Pathstone Holdings
DNLI icon

Pathstone Holdings’s Denali Therapeutics DNLI Stock Holding History

Pathstone Holdings’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
54,014
-2,311
-4% -$47.5K ﹤0.01% 1334
2026
Q1 		$1.08M Buy
56,325
+4,901
+10% +$97.5K ﹤0.01% 1368
2025
Q4 		$849K Buy
51,424
+5,594
+12% +$94.4K ﹤0.01% 1501
2025
Q3 		$665K Buy
45,830
+790
+2% +$11.4K ﹤0.01% 1625
2025
Q2 		$630K Buy
45,040
+6,735
+18% +$94.8K ﹤0.01% 1610
2025
Q1 		$521K Buy
38,305
+17,081
+80% +$327K ﹤0.01% 1698
2024
Q4 		$433K Buy
+21,224
New +$543K ﹤0.01% 1790

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's DNLI Position: Q2 2026 in Review

Pathstone Holdings reduced its Denali Therapeutics (DNLI) stake by 4.1% in Q2 2026, selling an estimated $47.5K and leaving 54,014 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Pathstone Holdings first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Pathstone Holdings held 54,014 shares of Denali Therapeutics worth $1.39M as of Q2 2026.
  • Pathstone Holdings sold 2,311 Denali Therapeutics shares in Q2 2026, an estimated $47.5K.
  • Denali Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1334 holding.
  • Pathstone Holdings first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.